In the pursuit of advanced preclinical research for renal diseases,Prisys Biotech offers an array of specialized non-human primate (NHP) models designed to support the development of innovative therapies for both acute and chronic kidney disease (AKI/CKD). As a specialized contract research organization (CRO), Prisys provides cutting-edge renal disease models that closely mirror human pathological conditions, facilitating translational research for effective drug development.
Why Non-Human Primate Models for Kidney Disease Research?
Kidney disease, encompassing a wide range of acute and chronic conditions, affects millions globally. The complex pathology of kidney diseases requires advanced models that accurately replicate human kidney function and disease progression. Non-human primates are ideal models for renal research due to their physiological and genetic similarities to humans, which enhance the reliability of preclinical data and the predictability of therapeutic outcomes.
Prisys Biotech's Renal Disease Model Portfolio
Prisys Biotech offers a suite of NHP models to address a wide spectrum of kidney pathologies, each designed to support the preclinical evaluation of therapeutic interventions. Key models in Prisys Biotech's renal disease portfolio include:
- Renal Ischemia and Reperfusion Models: These models simulate acute kidney injury through ischemia-reperfusion protocols, providing insights into injury mechanisms and recovery processes that are critical for drug development in AKI.
- Obstructive CKD and AKI-to-CKD Transition Models: Prisys offers models that allow researchers to study the transition from acute kidney injury to chronic kidney disease, reflecting the progressive nature of renal damage in humans.
- Renal Fibrosis Models: Prisys provides both interstitial and glomerular fibrosis models, enabling the investigation of fibrotic pathways and the evaluation of anti-fibrotic therapies for chronic kidney diseases.
- Systemic Complications: Cardiovascular and systemic complications, such as cardio-renal syndrome and IgA nephropathy, are common in kidney disease patients. Prisys' models incorporate these comorbidities, providing a comprehensive view of kidney disease's systemic effects.
Advanced Diagnostic Tools for Renal Research
In addition to its renal disease models, Prisys Biotech employs state-of-the-art diagnostic tools to enhance research precision:
- Imaging Capabilities: Prisys offers renal CT and MRI imaging to assess kidney morphology and pathology in real time.
- Glomerular Filtration Rate (GFR) Assessment: Accurate GFR measurements are essential for monitoring kidney function, and Prisys incorporates GFR testing as part of its comprehensive renal assessments.
- Biomarker Analysis: Prisys Biotech provides human biomarker analysis to support the development of targeted therapies, making the translational value of NHP studies even more relevant.
Case Study: Chronic Kidney Disease Model Development
Prisys Biotech has documented success in developing models that support CKD research. As highlighted in their recent study, Prisys has effectively utilized these models to simulate chronic kidney conditions, providing a robust platform for the evaluation of novel CKD therapies.
Why Choose the UUO Model for CKD Research?
The UUO modelinvolves surgically obstructing one ureter to create a controlled buildup of pressure in the kidney, leading to fibrosis-a hallmark of CKD. The UUO model in cynomolgus monkeys offers distinct advantages over traditional rodent models:
- Closer Physiological and Genetic Match to Humans: Cynomolgus monkeys have a genetic makeup similar to humans, which makes their response to disease and treatment highly translatable. In CKD research, this allows for the testing of next-generation therapies, such as gene and antibody treatments, that are often species-specific and may not cross-react effectively with rodent proteins.
- Comprehensive Fibrotic Response: The study on Prisys Biotech's UUO model demonstrates that fibrosis in cynomolgus monkeys progresses more similarly to human pathology compared to rodents, with advanced tubulointerstitial fibrosis developing within six weeks. This timeline provides a flexible disease window for testing therapeutic efficacy and tracking disease progression.
Key Insights from Prisys Biotech's UUO Model Study
Prisys Biotech's research on the UUO model, conducted in collaboration with UCB Pharma, revealed several critical findings that highlight the utility of this model for CKD and fibrosis research:
- Histological Similarities to Human Disease: The study found significant thickening of the tubular basement membrane, extensive collagen accumulation, and tubular atrophy. These changes are accompanied by fibroblast infiltration and increased transglutaminase 2 (TG2) activity-both characteristic markers of kidney fibrosis observed in human CKD patients.
- Measurable Biomarkers for Fibrosis: By assessing collagen levels, TG2 activity, and hydroxyproline content (a collagen marker), Prisys Biotech's model enables researchers to quantify fibrosis progression accurately. TG2 activity increased markedly after three weeks, with extracellular TG2 peaking by week four, indicating this time frame as optimal for evaluating anti-fibrotic therapies before fibrosis plateaus.
- TG2 as a Mechanistic Target: TG2, an enzyme that promotes fibrosis by cross-linking extracellular matrix proteins, showed a strong correlation with fibrosis markers in the UUO model. This makes TG2 an important target for human-specific anti-fibrotic therapeutics and underscores the translational potential of the model for testing treatments aimed at slowing fibrosis progression.
Leveraging Prisys Biotech's UUO Model for Drug Development
Prisys Biotech's UUO model in cynomolgus monkeys is a unique asset for pharmaceutical and biotech companies working on kidney disease therapies. It enables:
- Precise Evaluation of Human-Specific Therapies: Ideal for biologics and antibody-based treatments that may not be compatible with rodent models.
- Detailed Tracking of Disease Progression: The model's timeline and measurable biomarkers offer a robust framework for testing efficacy in both early and later stages of fibrosis.
Partner with Prisys Biotech for Innovative Renal Research
With Prisys Biotech's renal disease models, pharmaceutical and biotech companies can conduct reliable preclinical assessments to support the development of effective kidney disease treatments. For more information or to discuss specific research needs, please contact Prisys Biotech to arrange a consultation.
